No, Do Not Write a Sig to Stop Valacyclovir at the End of an Outbreak for Patients on Chronic Suppressive Therapy
Patients on chronic suppressive therapy should continue their daily valacyclovir regimen without interruption when breakthrough outbreaks occur. The suppressive dose and episodic treatment dose serve different purposes and should not be confused.
Understanding the Two Treatment Strategies
The evidence clearly distinguishes between two separate approaches to managing recurrent genital herpes 1, 2:
Episodic Therapy (Not Your Patient)
- For patients NOT on suppressive therapy
- Valacyclovir 500 mg twice daily for 3-5 days 1, 2
- Initiated at first sign of prodrome or lesions
- Patient should have medication on hand to start immediately
Suppressive Therapy (Your Patient)
- Daily continuous dosing: 500 mg to 1 gram once daily 1, 2
- Reduces recurrence frequency by ≥75% 1
- Does NOT eliminate all outbreaks—breakthrough recurrences can still occur
What to Do When Breakthrough Outbreaks Occur
Continue the daily suppressive dose unchanged. The guidelines do not recommend stopping suppressive therapy or switching to episodic dosing during breakthrough outbreaks 1. Here's why:
- Suppressive therapy works by maintaining consistent antiviral drug levels to reduce viral reactivation and shedding
- Interrupting daily therapy defeats the purpose of suppression
- The breakthrough outbreak will resolve while continuing suppressive therapy
- Stopping and restarting creates gaps in viral suppression
When to Consider Discontinuing Suppressive Therapy
After 1 year of continuous suppressive therapy, discuss discontinuation with the patient to reassess their psychological adjustment and recurrence rate, as outbreak frequency naturally decreases over time in many patients 1. This is a planned reassessment, not a response to individual outbreaks.
Important Caveats:
- The 1998 CDC guidelines noted "insufficient experience with famciclovir and valacyclovir prevents recommendation of these drugs for greater than 1 year" 1
- However, this was based on limited data at that time; subsequent research has demonstrated long-term safety 3, 4, 5
- For HIV-infected patients with CD4+ ≥100 cells/mm³, the dose is 500 mg twice daily 2
Common Pitfall to Avoid
Do not confuse suppressive therapy with episodic therapy. The most common error is thinking that patients on suppressive therapy should switch to episodic dosing (500 mg twice daily for 3-5 days) when they have a breakthrough outbreak. This approach:
- Interrupts the continuous viral suppression
- May lead to more frequent recurrences
- Contradicts the purpose of suppressive therapy
Practical Prescription Guidance
For your patient on chronic suppressive therapy experiencing a breakthrough outbreak:
Sig: Continue taking 500 mg (or 1 gram) by mouth once daily as prescribed. Do not stop or change dosing during outbreaks.
If you need to provide reassurance or additional instructions, you might add: "Breakthrough outbreaks can occur even on suppressive therapy. Continue your daily medication without interruption."